How to access Olumiant from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient — adult or adolescent — with severe alopecia areata may be evaluated by their treating dermatologist for Olumiant (baricitinib). Olumiant is FDA-approved for severe alopecia areata in adults, and is developed and marketed by Eli Lilly in partnership with Incyte. In India, baricitinib has a long history as an RA therapy and is locally available in that context; what is less uniformly available is a dermatology-led prescription for the alopecia areata indication at the specific strength and duration the patient needs. Where that gap exists, a named-patient import pathway is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Olumiant is an oral JAK1/JAK2 inhibitor taken once daily. For severe alopecia areata, the FDA-labeled adult dose is typically 2 mg daily with escalation to 4 mg as clinically appropriate. Response develops over months, and continued therapy is generally required to sustain regrowth. Your dermatologist confirms severity (SALT score documentation), baseline screening (TB, lipids, infection), and a monitoring plan in line with FDA labeling and the JAK-class risk-benefit discussion.
Is Olumiant legally importable into India?
Yes — through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. The route permits a registered medical practitioner to request import of a medicine not locally registered for that specific indication or strength when the medicine is approved by a recognised reference authority (FDA qualifies), no clinically equivalent registered option fits, and chain of custody is documented.
For baricitinib in severe alopecia areata, diaspora-supported import is a common use-case because the originator product at the specific US-label dosing is often sourced abroad even when an RA-label version is on the local market.
How the pathway works, step by step
- Consultation with your treating dermatologist. Severity documentation (SALT score) and clinical rationale.
- Pre-treatment screening. TB, lipids, vaccination status, and infection screening per labeling.
- CDSCO application. The physician or hospital files the personal-use / named-patient application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Shipment. Olumiant is an oral tablet with standard storage; shipment includes tamper-evident packaging and end-to-end chain-of-custody documentation.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming severe alopecia areata diagnosis, SALT documentation, prior therapies, and Olumiant as the indicated treatment
- Verification of their Indian medical registration (NMC)
- Patient identifier and address for the import record
- Pre-treatment screening results
- Planned dosing regimen and follow-up cadence
Reserve Meds provides a physician documentation kit that bundles the templates Indian customs and CDSCO reviewers expect to see for JAK-class therapies, including the cardiovascular and infection-screening block expected for this drug class.
Costs and timing
Olumiant's US cash-pay reference price for a 30-tablet month supply at 2 mg sits in a broad indicative range of roughly USD 2,800–3,500. The 4 mg strength is priced higher. International logistics, customs clearance, CDSCO documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted and customs processing begins. Refills ship on a rolling basis.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: many Indian alopecia areata patients are young adults whose families abroad — US, UAE, UK — are helping fund private specialty care. Our concierge case lead is set up to include every designated family member on coordination and document flow.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Olumiant specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for CDSCO / customs review.
- Logistics. Tamper-evident, internationally tracked shipment.
- Concierge case lead. A named point of contact for the family wherever based.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating dermatologist.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation.
Isn't baricitinib available locally for RA? Yes, generics exist in India for the RA indication. The originator Olumiant branded product and the specific dosing the US label uses for severe alopecia areata is often what diaspora-supported families source through NPP. Your physician will decide what is clinically right for your case.
What about JAK-class warnings? The FDA boxed warning applies across JAK inhibitors. Your physician assesses risk-benefit and monitors accordingly.
Can the family abroad pay directly? Yes. Diaspora-supported invoicing is common for this use-case, and we issue invoicing that family members in the US, UAE, UK, Canada, and elsewhere can settle directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Olumiant coordination in India.
Add me to the Olumiant waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.